ICON’s novel RNA-based NGS assay, Dup-Seq BCR::ABL1, represents a significant advancement in the management of CML patients.

Single-cell analysis of CML patients bone marrow at diagnosis reveals coexistence of CD26-CD35+ healthy stem cells and CD26+CD35- CML stem cells, and how the ratio between these impacts TKI response.

Based on RNA technology, ICON’s new assay offers huge improvements on how CML is monitored ... NGS assay known as Dup-Seq BCR::ABL1. This innovative assay enables the identification of both ...

Food security, healthcare, electricity, and employment are among the many fundamental human rights to which innovative technology is being applied—and making a difference. More than a billion ...

Developed by Ascentage Pharma, olverembatinib is the first China -approved third-generation BCR:ABL1 inhibitor, currently being jointly commercialized in China by Ascentage Pharma and Innovent ...

A financial expert, Wuraola Olaleye, has said the integration of advanced financial strategies with innovative technology is essential for transforming the finance landscape. Olaleye, in a ...

AutoStore believes its automated fulfillment solutions exemplify the type of innovative technology that Gartner emphasizes as essential for modern retail operations. “Our commitment to ...

The McGraw Center is at the heart of efforts to integrate innovative educational technologies into the academic experience. The center encourages the exploration of new media and digital tools in and ...

and chronic myeloid leukemia (CML). This innovative technology offers significant advantages over traditional diagnostic methods, especially in resource-limited settings. By providing timely and ...

Chase Mining Corporation Limited (AU:GCM) has released an update. Chase Mining Corporation Limited has acquired an innovative technology to ...